Immunogenicity of an inactivated hepatitis A vaccine in infants and young children

Pediatric Infectious Disease Journal

Volumn 26, Issue 2, 2007, Pages 116-122

  Bell, Beth P ^a   Negus, Susan ^b   Fiore, Anthony E ^a   Plotnik, Julia ^c   Dhotre, Kathy Boaz ^a   Williams, James ^b   Shapiro, Craig N ^a   McMahon, Brian J ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Liver Disease and Hepatitis Program   (United States)

^c Anchorage Neighborhood Health Center   (United States)

Author keywords

Hepatitis A; Hepatitis A virus; Immunogenicity; Vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INACTIVATED VIRUS VACCINE; MATERNAL ANTIBODY; PARACETAMOL; POLIOMYELITIS VACCINE;

ANTIBODY BLOOD LEVEL; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; DRUG SUBSTITUTION; FEVER; GROUPS BY AGE; HEPATITIS A; HEPATITIS A VIRUS; HUMAN; IMMUNOGENICITY; INFANT; INJECTION SITE PAIN; IRRITABILITY; MAJOR CLINICAL STUDY; NEWBORN; NORMAL HUMAN; PRENATAL EXPOSURE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; TREATMENT RESPONSE; VACCINATION;

AGE FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS A VIRUS; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNIZATION SCHEDULE; INFANT;

EID: 33846573721     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000253253.85640.cc     Document Type: Article

References (31)

1. Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: Model-based estimates and implications for childhood immunization. Pediatrics. 2002;109:839-845.
2. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1996;45:1-30.
3. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1999;48:1-37.
4. Wasley A, Samandari T, Bell BP. Hepatitis A in the United States in the era of vaccination. JAMA. 2005;294:194-201.
5. Averhoff F, Shapiro CN, Bell BP, et al. The effectiveness of routine childhood hepatitis A immunization in the prevention of hepatitis A. JAMA. 2001;286:2968-2973.
6. Samandari T, Bell BP, Armstrong GA. Quantifying the impact of hepatitis A immunization in the United States, 1995-2001. Vaccine. 2004;22:4342-4350.
7. Centers for Disease Control and Prevention. Notice to readers: Approval of VAQTA® (hepatitis A vaccine, inactivated) for children aged ≥1 year. MMWR Morb Mortal Wkly Rep. 2005;54:1026.
8. Centers for Disease Control and Prevention. Notice to readers: FDA approval of Havrix® (hepatitis A vaccine, inactivated) for persons aged 1-18 years. MMWR Morb Mortal Wkly Rep. 2005;54:1236.
9. Letson GW, Shapiro CN, Kuehn D, et al. Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. J Pediatr. 2004;144:327-332.
10. Dagan R, Amir J, Mijalovsky A, et al. Immunization against hepatitis A in the first year of life: Priming despite the presence of maternal antibody. Pediatr Infect Dis J. 2000;19:1045-1052.
11. Piazza M, Safary A, Vegnente A, et al. Safety and immunogenicity of hepatitis A vaccine in infants: A candidate for inclusion in the childhood vaccination programme. Vaccine. 1999;17:585-588.
12. Troisi CL, Hollinger FB, Krause DS, Pickering LK. Immunization of seronegative infants with hepatitis A vaccine (HAVRIX; SKB): A comparative study of two dosing schedules. Vaccine. 1997;15:1613-1617.
13. Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA. 2005;294:202-210.
14. Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and the Gambia. World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine. J Infect Dis. 1995;171:1097-1106.
15. Hummel KB, Erdman DD, Heath JL, Bellini WJ. Baculovirus expression of the nucleoprotein gene of measles virus and the utility of the recombinant protein in diagnostic enzyme immunoassays. J Clin Microbiol. 1992;30:2874-2880.
16. Greenberg DP, Vadheim CM, Partridge S, Chang SJ, Chiu CY, Ward JI. Immunogenicity of Haemophilus influenzae type b tetanus toxoid conjugate vaccine in young infants. The Kaiser-UCLA Vaccine Study Group. J Infect Dis. 1994;170:76-81.
17. Lieberman JM, Greenberg DP, Wong VK, Partiedge S, Chang SJ, Chiu CY, Ward JI. Effect of neonatal immunization with diphtheria and tetanus toxoids on antibody responses to Haemophilus influenzae type b conjugate vaccines. J Pediatr. 1995;126:198-205.
18. Phipps DC, West J, Eby R, Koster M, Madore DV, Quataert SA. An ELISA employing a Haemophilus influenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen binding assay. J Immunol Methods. 1990;135:121-128.
19. Deen JL, Mink CA, Cherry JD, et al. Household contact study of Bordetella pertussis infections. Clin Infect Dis. 1995;21:1211-1219.
20. Hodder SL, Cherry JD, Mortimer EA Jr, et al. Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents. Clin Infect Dis. 2000;31:7-14.
21. Manclark C, Meade BD, Burstyn D. Serological responses to Bordetella pertussis. In: RNR, FH, FJL, eds. Manual of Clinical Laboratory Immunology, 3rd ed. Washington, DC: American Society for Microbiology; 1986:388-394.
22. Meade BD, Adamadia D, Edwards KM, Romani TA, Freyja L. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics. 1995;96:570-575.
23. Lieberman JM, Chang SJ, Partridge S, et al. Kinetics of maternal hepatitis A antibody decay in infants: Implications for vaccine use. Pediatr Infect Dis J. 2002;21:347-348.
24. Van der Wielen M, Van Damme P, Collard F. A two dose schedule for combined hepatitis A and hepatitis B vaccination in children ages one to eleven years. Pediatr Infect Dis J. 2000;19:848-853.
25. Williams JL, Bruden DA, Cagle HH, et al. Hepatitis A vaccine: Immunogenicity following administration of a delayed immunization schedule in infants, children, and adults. Vaccine. 2003;21:3208-3211.
26. Nolan T, Bernstein H, Blatter MM, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age. Pediatrics. 2006;118:602-609.
27. Iwarson S. Are we giving too many doses of hepatitis A and B vaccines? Vaccine. 2002;20:2017-2018.
28. Fiore AE, Shapiro CN, Sabin K, et al. Hepatitis A vaccination of infants: Effect of maternal antibody status on antibody persistence and response to a booster dose. Pediatr Infect Dis J. 2003;22:354-359.
29. Kanra G, Yalcin SS, Kara A, et al. Hepatitis A booster vaccine in children after infant immunization. Pediatr Infect Dis J. 2002;21:727-730.
30. Fan PC, Chang MH, Lee PI, Safary A, Lee CY. Follow up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: Results after 5 years. Vaccine. 1998;16:232-235.
31. Centers for Disease Control and Prevention. Prevention of Hepatitis A Through Active or Passive Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55.